Cisplatin in cancer therapy: molecular mechanisms of action.

doi:10.1016/j.ejphar.2014.07.025

Paper

Cisplatin in cancer therapy: molecular mechanisms of action.

Published Oct 5, 2014 · Shaloam Dasari, P. Tchounwou

European journal of pharmacology

Q1 SJR score

4,245

Citations

108

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Rigorous Journal

Highly Cited

Study Snapshot

Cisplatin effectively treats various human cancers by interfering with DNA repair mechanisms and inducing apoptosis in cancer cells, but has undesirable side effects.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Cisplatin in cancer therapy: molecular mechanisms of action.

Sign up to use Study Snapshot

References

Downregulation of HIPK2 Increases Resistance of Bladder Cancer Cell to Cisplatin by Regulating Wip1

Downregulation of HIPK2 in bladder cancer cells increases resistance to cisplatin, offering a new target for bladder cancer chemotherapy.

Role of Autophagy in Cisplatin Resistance in Ovarian Cancer Cells*

Cisplatin-induced autophagy contributes to cisplatin resistance in ovarian cancer cells, and targeting autophagy may help overcome cisplatin resistance in ovarian cancer cells.

Rac1 as a potential therapeutic target for chemo-radioresistant head and neck squamous cell carcinomas (HNSCC)

Inhibiting Rac1 activity may improve chemosensitivity and reduce tumor recurrence risk in chemo-radioresistant HNSCC patients.

AQP5 silencing suppresses p38 MAPK signaling and improves drug resistance in colon cancer cells

AQP5 silencing improves drug resistance in colon cancer cells, suggesting it as a potential target for improving drug resistance in colon cancer cells.

Inhibition of EGFR-induced glucose metabolism sensitizes chondrosarcoma cells to cisplatin

Inhibiting EGFR-induced glucose metabolism can sensitize chondrosarcoma cells to cisplatin, potentially improving treatment outcomes for chondrosarcoma patients.

Citations